An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL).
Jeffrey Alan Sosman
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Research Funding - Bristol-Myers Squibb
Salvador Martin-Algarra
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Jedd D. Wolchok
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Research Funding - Bristol-Myers Squibb
William Howard Sharfman
Consultant or Advisory Role - Merck
Shailender Bhatia
Research Funding - Bristol-Myers Squibb
F. Stephen Hodi
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Wen-Jen Hwu
Research Funding - Bristol-Myers Squibb
Thomas Gajewski
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Craig L. Slingluff
No relevant relationships to disclose
Howard Kaufman
No relevant relationships to disclose
Manish Gupta
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Analia McGirr
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Christine E. Horak
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Christoph Matthias Ahlers
Employment or Leadership Position - Bristol-Myers Squibb
Jon M. Wigginton
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Walter John Urba
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb